Loading asset research
RenovoRx Inc. Common Stock
RNXTNasdaq · USD · StocksQuote as of · Exchange session not verified$1.76
-0.56%
Today
RNXT
Loading 1D prices…
Market cap
$79.4M
Volume
1.2M
52w high
$2.5952w low
$0.701Company profile
RenovoRx Inc. Common Stock
RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. The company was founded in 2009 and is headquartered in Mountain View, California.
Sector
Health Care
Industry
Pharmaceutical Preparations
Exchange
Nasdaq
Display currency
USD
Location
Mountain View, CA, United States
Employees
17
Fiscal year end
1231
CIK
1574094
Session & valuation
Open$1.77
Previous close$1.77
Day high$1.82
Day low$1.67
30-day avg. volume1.2M
Outstanding shares45.1M
Diluted EPS-$0.32
Latest annual period
P/E (trailing)-5.50
P/E (forward)-14.67
Price / book8.84
Beta1.12
Dividend yield—
Deterministic peer set
Companies with SEC SIC 2834
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| MAIAMAIA Biotechnology Inc. Common Stock | $79.1M | $0.00 | — | -$0.70 | -1.53% | Buy |
| OSTXOS Therapies Incorporated Common Stock | $78.6M | $0.00 | — | -$0.98 | -7.69% | Buy |
| TELOTelomir Pharmaceuticals Inc. Common Stock | $80.5M | $0.00 | — | -$0.33 | -0.85% | Unrated |
| ALDXAldeyra Therapeutics Inc. Common Stock | $80.8M | $0.00 | — | -$0.56 | -8.22% | Buy |
| IBIOiBio Inc. Common Stock | $77.5M | $100K | -33044.00% | -$0.32 | -0.38% | Buy |